- Home
- CLH vs UTHR Comparison
CLH vs UTHR Comparison
Compare CLH & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLH
- UTHR
- Stock Information
- Founded
- CLH 1980
- UTHR 1996
- Country
- CLH United States
- UTHR United States
- Employees
- CLH N/A
- UTHR N/A
- Industry
- CLH Environmental Services
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- CLH Industrials
- UTHR Health Care
- Exchange
- CLH Nasdaq
- UTHR Nasdaq
- Market Cap
- CLH 14.0B
- UTHR 16.2B
- IPO Year
- CLH 1987
- UTHR 1999
- Fundamental
- Price
- CLH $230.59
- UTHR $359.23
- Analyst Decision
- CLH Strong Buy
- UTHR Buy
- Analyst Count
- CLH 8
- UTHR 14
- Target Price
- CLH $268.50
- UTHR $370.86
- AVG Volume (30 Days)
- CLH 318.3K
- UTHR 313.6K
- Earning Date
- CLH 02-19-2025
- UTHR 02-19-2025
- Dividend Yield
- CLH N/A
- UTHR N/A
- EPS Growth
- CLH 15.34
- UTHR 25.10
- EPS
- CLH 7.68
- UTHR 22.72
- Revenue
- CLH $5,797,005,000.00
- UTHR $2,756,200,000.00
- Revenue This Year
- CLH $10.09
- UTHR $26.32
- Revenue Next Year
- CLH $6.01
- UTHR $10.37
- P/E Ratio
- CLH $30.02
- UTHR $15.82
- Revenue Growth
- CLH 8.37
- UTHR 25.04
- 52 Week Low
- CLH $161.39
- UTHR $208.62
- 52 Week High
- CLH $267.11
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- CLH 34.88
- UTHR 43.90
- Support Level
- CLH $242.83
- UTHR $358.82
- Resistance Level
- CLH $250.37
- UTHR $383.00
- Average True Range (ATR)
- CLH 6.21
- UTHR 9.97
- MACD
- CLH -2.08
- UTHR -0.80
- Stochastic Oscillator
- CLH 3.24
- UTHR 29.51
About CLH Clean Harbors Inc.
Clean Harbors Inc is an environmental and industrial services provider. It provides parts cleaning and related environmental services to commercial, industrial, and automotive customers. Its business segments are Environmental Services and Safety-Kleen Sustainability Solutions. The company generates the majority of its revenues from the Environmental Services segment.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.